Progress in PDE4 targeted therapy for inflammatory diseases / 浙江大学学报·医学版
Journal of Zhejiang University. Medical sciences
; (6): 353-358, 2014.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-251696
Responsible library:
WPRO
ABSTRACT
cAMP-specific phosphodiesterase type 4 (PDE4) is one of the hot targets for treatment of inflammatory diseases. PDE4 inhibitors can suppress inflammation by increasing the concentration of cAMP in inflammatory cells. The efficacy and safety evaluations of several PDE4 inhibitors are currently carried on in clinical trials, for example GSK256066 in asthma, roflumilast and GSK256066 in chronic obstructive pulmonary disease, tetomilast in inflammatory bowel disease, and apremilast in dermatitis and arthritis etc. This article reviews the recent progress on PDE4-targeted therapy for inflammatory diseases.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Pharmacology
/
Arthritis
/
Asthma
/
Sulfones
/
Thalidomide
/
Thiazoles
/
Benzamides
/
Inflammatory Bowel Diseases
/
Cyclopropanes
/
Pulmonary Disease, Chronic Obstructive
Limits:
Humans
Language:
Chinese
Journal:
Journal of Zhejiang University. Medical sciences
Year:
2014
Document type:
Article